Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115737) titled 'Construction and Application of a Prediction Model for Immune Checkpoint Inhibitor-Related Adverse Events' on Dec. 30, 2025.
Study Type: Observational study
Study Design:
Sequential
Primary Sponsor: Henan Cancer Hospital
Condition:
Gastrointestinal Tumors
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-01-01
Target Sample Size: Observation group:150;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=302385
Disclaimer: Curated by HT Syndication....